



# SANDU PHARMACEUTICALS LIMITED

CIN:L24233GA1985PLC001587

Regd. Office: Plot Nos. 25, 26, 29 & 30, Pilerne Industrial Estate, Marra, Saligao, Bardez, Goa 403511.

Tel: +91 832 2407474 / 6715000, E-mail: sandupharma@sandu.in, Website: www.sandu.in

Ref:Corp.sec/BSE/2019-20/1109

Date: 17.02.2020

To,  
Department of Corporate Services  
Bombay Stock Exchange Limited,  
Phirojshah Jeejobhoy tower,  
Dalal Street,  
Mumbai-400001

Sub:Newspaper Publication in respect of Unaudited Financial Results as per regulation 30 of SEBI (LODR)

Sir,

We are sending herewith the Newspaper cutting in respect of Unaudited Financial Results for the Quarter ended 31<sup>st</sup> December 2019 in respect of the Board Meeting held on 14<sup>th</sup> Feb 2020 published in the "Goadoot" and "Navhind Times" dated 16<sup>th</sup> February 2020.

You are requested to take the same on record and obliged.

Thanking you,

Yours Faithfully,

For Sandu Pharmaceuticals Limited



Encl: - As Above



AN ISO 9001:2015 CERTIFIED ORGANISATION

Corporate Office: P. B. No. 17201, Sandu Nagar, D. K. Sandu Marg, Chembur, Mumbai – 400 071.

Tel.: +91 22 2528 4402 / 3306, E-mail: info@sandu.in



# THE HINDU

THE NEWSPAPER YOU CAN TRUST

# TIMERS

COVERING GOA SINCE 1963

## SANDU PHARMACEUTICALS LTD.

СANDU PHARMACEUTICALS LTD. (INCORPORATED IN INDIA)  
 SANDU PHARMACEUTICALS LTD. (INCORPORATED IN INDIA)  
 SANDU PHARMACEUTICALS LTD. (INCORPORATED IN INDIA)  
 SANDU PHARMACEUTICALS LTD. (INCORPORATED IN INDIA)

### EXTRACT OF STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTH ENDED 31.12.2019. (In Lakhs)

Sl. No.	Particulars	Quarter Ended 30.09.2019	Year to date figures 31.12.2019	Comparing 12 months ended 31.12.2018
1	Total Income from Operations (Net)	1531.06	3776.59	1433.86
2	Net Profit/Loss for the period (before Tax, Exceptional and/or Extraordinary Items)	21.72	84.14	16.34
3	Net Profit/Loss for the period before Tax (After Exceptional and/or Extraordinary Items)	21.72	83.70	16.34
4	Net Profit / (Loss) for the period after tax (After Exceptional and/or Extraordinary Items)	16.68	69.90	8.32
5	Total Comprehensive Income for the period (Including Profit/Loss, for the period (before and after other comprehensive income (after tax))	16.68	76.02	11.66
6	Equity Share Capital (face value Rs. 10/-)	708.50	708.10	708.10
7	Reserves according to Indian Accounting Standards as per Schedule III of Companies Act, 2013 (including other reserves)	1,311.96	1,513.30	1,298.39
8	Other Reserves	0.22	0.99	0.37
9	Total	0.22	0.99	0.37

The above is an extract of the detailed format of the unaudited financial results for the Quarter ended 31.12.2019. The detailed format of the unaudited financial results for the Quarter ended 31.12.2019 is available on the Company's website [www.sandu.in](http://www.sandu.in) and on the website of the stock exchange [www.bseindia.com](http://www.bseindia.com).

Date: 14/02/2020  
 Place: Mumbai

Umesh Sandu  
 Managing Director  
 DIN: 07131441

FOR SANDU PHARMACEUTICALS LTD.

आपली माणसं, आपलं दैनिक!

# जाणदून



www.goardo

गाईनात : goac

गांमदनीम : goam



रांीने : १० शंम - ₹ ४१.००४

राणी : रविवार, १६ फेब्रुवारी २०२० वर्ष : १५ अंक : २६५ पाने : ८  
 तापमान : कमल - ३४.०°से. तापमान : किमान - २२.२°से. आर्द्रता : ८६ टक्के

**SANDU PHARMACEUTICALS LTD.**  
 CHAUHAN, SION, COAST  
 HEAD OFFICE: PLOT NO. 22, 23 & 24, KEMPE INDUSTRIAL ESTATE, BHAMIA,  
 SIKOLIA, SANGLI-423111.  
 email: info@sandu.co.in www.sandu.co.in tel: 0213171200

**EXTRACT OF STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTH ENDED 31.12.2019 (in Lakhs)**

Sr. No.	Particulars	Quarter Ended 31.03.2019	Year to date figures 31.12.2019	Comparative figures for the previous year ended 31.12.2018
1	Total income from Operations (Net)	1331.09	3779.28	4420.35
2	Net Expenditure for the period (Net) - Exceptional and/or Extraordinary Items	21.72	94.14	18.34
3	Net Profit/Loss for the period before the effect of Exceptional and/or Extraordinary Items	1309.37	3685.14	4402.01
4	Net Profit/Loss (Less) in the period after the effect of Exceptional and/or Extraordinary Items	15.65	69.90	6.52
5	Total Comprehensive Income for the period (Comprising Profit/Loss for the period (after tax) and other comprehensive income (after tax))	15.65	75.02	11.89
6	Reserve Shortfall (Less) value Rs. (16)	708.10	708.10	708.10
7	Income tax expense (Provision) Reserve in respect of Income Tax (Less) value of Rs. (16) (net)	1,313.36	1,313.36	1,296.39
8	Change in net assets (Less) value of Rs. (16) (net) for continuing and discontinued operations	0.22	0.06	0.12
9	Net Asset Value	0.22	0.89	2.13

The above is an extract of the abstract form of the Unaudited financial results for a Quarter ended 31st December 2019 filed with the stock exchanges on 14th February 2020 under Regulation 23 of the SEBI (Listing Obligations and Disclosures Requirements) 2015. The full Regulatory Form of the Sandu Pharm Financial Results are available on the Company's website www.sandu.co.in and on the website of the stock exchanges www.secdatabase.com.

FOR SANDU PHARMACEUTICALS LTD.  
 Sd/-  
 Umesh Sandu  
 Managing Director  
 DIN: 0712154

Dated: 14/02/2020  
 Place: Mumbai